U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

DUBLIN, March 21, 2024 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

Medtronic will now ask the federal court in the Central District of California, where Medtronic's patent infringement lawsuit is pending, to lift its stay on the lawsuit and proceed to trial on the five valid and affirmed patents so Medtronic can present its case in front of a jury.

"It's now past time for Axonics to stand up in a court of law and take responsibility for its unauthorized use and infringement of Medtronic's intellectual property," said Mira Sahney, president of the pelvic health business in the neuroscience portfolio at Medtronic. "We respect the intellectual property of innovators, and our patent system exists to benefit society by encouraging the kind of innovation that Medtronic invests in. We are pleased with the PTAB's decision, and we are confident that the evidence at trial will show that Axonics improperly used and profited from Medtronic's patented technology."

Medtronic also <u>filed a complaint with the U.S. International Trade Commission</u>(ITC) along with a parallel action in the U.S. District Court for the District of Delaware to block Axonics from improperly importing and selling products that infringe two additional Medtronic patents related to the MRI compatibility of implantable medical devices.

## **About Medtronic**

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered inDublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit <a href="https://www.Medtronic.com">www.Medtronic.com</a> and follow Medtronic on <a href="https://www.Medtronic.com">LinkedIn</a>.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

## Contacts:

Laurel Hood Ryan Weispfenning
Public Relations
+1-763-514-0249 +1-763-505-4626

https://news.medtronic.com/2024-03-21-U-S-Patent-Office-rejects-Axonics-latest-challenge-to-Medtronic-patents